[{"address1": "4902 Eisenhower Boulevard", "address2": "Suite 125", "city": "Tampa", "state": "FL", "zip": "33634", "country": "United States", "phone": "813 286 7900", "fax": "813 286 7904", "website": "https://www.oragenics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.", "fullTimeEmployees": 5, "irWebsite": "http://www.oragenics.com/?q=investors", "maxAge": 86400, "priceHint": 4, "previousClose": 1.45, "open": 1.57, "dayLow": 1.4, "dayHigh": 1.57, "regularMarketPreviousClose": 1.45, "regularMarketOpen": 1.57, "regularMarketDayLow": 1.4, "regularMarketDayHigh": 1.57, "beta": 0.575, "forwardPE": -0.13333334, "volume": 43825, "regularMarketVolume": 43825, "averageVolume": 108045, "averageVolume10days": 28590, "averageDailyVolume10Day": 28590, "bidSize": 1000, "askSize": 900, "marketCap": 6452194, "fiftyTwoWeekLow": 1.0, "fiftyTwoWeekHigh": 7.74, "priceToSalesTrailing12Months": 312.77298, "fiftyDayAverage": 1.5868, "twoHundredDayAverage": 2.9688, "currency": "USD", "enterpriseValue": 6099772, "floatShares": 3945205, "sharesOutstanding": 4480690, "sharesShort": 60569, "sharesShortPriorMonth": 35608, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0135, "heldPercentInsiders": 0.23231001, "heldPercentInstitutions": 0.10158, "shortRatio": 0.62, "shortPercentOfFloat": 0.0153, "impliedSharesOutstanding": 4480690, "bookValue": 0.23, "priceToBook": 6.2608695, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -20261732, "trailingEps": -8.47, "forwardEps": -10.8, "lastSplitFactor": "1:60", "lastSplitDate": 1674432000, "enterpriseToRevenue": 295.689, "enterpriseToEbitda": -0.298, "52WeekChange": -0.57270026, "SandP52WeekChange": 0.26238096, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "OGEN", "underlyingSymbol": "OGEN", "shortName": "Oragenics Inc.", "longName": "Oragenics, Inc.", "firstTradeDateEpochUtc": 1077719400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "747ffae6-a5e0-3f81-bef4-ef8201719134", "messageBoardId": "finmb_774436", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.44, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 2071989, "totalCashPerShare": 0.462, "ebitda": -20437256, "totalDebt": 126840, "quickRatio": 2.28, "currentRatio": 2.689, "totalRevenue": 20629, "debtToEquity": 4.832, "revenuePerShare": 0.008, "returnOnAssets": -1.6328, "returnOnEquity": -3.14875, "freeCashflow": -10301939, "operatingCashflow": -8246434, "operatingMargins": -991.8169, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]